We are analyzing https://link.springer.com/article/10.1007/s00277-004-0855-x.

Title:
Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study | Annals of Hematology
Description:
The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (>10%) low (<60%) expression of Ki-67, and high TP53 protein expression (>75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Health & Fitness
Photography

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We find it hard to spot revenue streams.

Not all websites focus on profit; some are designed to educate, connect people, or share useful tools. People create websites for numerous reasons. And this could be one such example. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

lymphoma, google, scholar, pubmed, expression, prognostic, bcl, nonhodgkins, article, bcell, diffuse, lymphomas, large, aggressive, cas, lund, patients, study, clinical, oncol, blood, information, pglycoprotein, protein, department, privacy, cookies, content, jerkeman, anderson, trial, access, clin, significance, cancer, hospital, publish, research, search, assessment, factors, group, april, dictor, immunohistochemical, outcome, oncology, university, data, log,

Topics {✒️}

month download article/chapter high-grade b-cell lymphomas international prognostic index cell-cycle regulator proteins aggressive b-cell lymphoma diffuse large cell b-cell lymphoma trial comparing chop biological prognostic factors chop versus macop full article pdf privacy choices/manage cookies lymphoma classification project related subjects b-cell cavallin-ståhl department high-grade osteosarcomas bcl-2 gene rearrangement major histologic subtypes epoch chemotherapy elisabeth nilsson foundation population-based study european economic area scope submit manuscript stage ii-iv adequate paraffin blocks human normal tissues tumor proliferation expert technical assistance norwegian radium hospital conditions privacy policy check access gela-lnh87 trial instant access high bcl2 expression clinically relevant information van krieken jh article annals swedish cancer society bcl-2 protein expression kluin-nelemans jc biological markers accepting optional cookies failure-free survival author information authors martinez-montero jc clinical drug resistance p53 protein expression journal finder publish p-glycoprotein

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study
         description:The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (>10%) low (<60%) expression of Ki-67, and high TP53 protein expression (>75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression.
         datePublished:2004-04-14T00:00:00Z
         dateModified:2004-04-14T00:00:00Z
         pageStart:414
         pageEnd:419
         sameAs:https://doi.org/10.1007/s00277-004-0855-x
         keywords:
            BCL2
            Diffuse large B-cell lymphoma
            P-glycoprotein
            Proliferation
            TP53
            Hematology
            Oncology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb1.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb2.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb3.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb4.gif
         isPartOf:
            name:Annals of Hematology
            issn:
               1432-0584
               0939-5555
            volumeNumber:83
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:M. Jerkeman
               affiliation:
                     name:Lund University Hospital
                     address:
                        name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:H. Anderson
               affiliation:
                     name:Lund University Hospital
                     address:
                        name:Department of Cancer Epidemiology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Dictor
               affiliation:
                     name:Lund University Hospital
                     address:
                        name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:S. Kvaløy
               affiliation:
                     name:Norwegian Radium Hospital, Montebello
                     address:
                        name:Department of Oncology, Norwegian Radium Hospital, Montebello, Oslo, Norway
                        type:PostalAddress
                     type:Organization
               type:Person
               name:M. Åkerman
               affiliation:
                     name:Lund University Hospital
                     address:
                        name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
               name:E. Cavallin-Ståhl
               affiliation:
                     name:Lund University Hospital
                     address:
                        name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Assessment of biological prognostic factors provides clinically relevant information in patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study
      description:The purpose of this study was to investigate the prognostic effects of four biological markers, BCL2, TP53, Ki-67, and P-glycoprotein, and their possible clinical relevance in addition to the international prognostic index (IPI) in diffuse large B-cell lymphoma (DLBCL). A total of 405 patients with aggressive lymphoma, stage II-IV, between 18 and 67 years, were randomized in a trial comparing CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) with MACOP-B (methotrexate, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Of these, 267 cases were classified as DLBCL, with adequate paraffin blocks available in 207 cases, enabling immunohistochemical assessment of the expression of BCL2, TP53, P-glycoprotein, and Ki-67. In a multivariate analysis, stratified for IPI, high BCL2 expression (>10%) low (<60%) expression of Ki-67, and high TP53 protein expression (>75%) were shown to provide additional prognostic information with regard to overall or failure-free survival. We found no association between expression of P-glycoprotein and outcome. Assessment of BCL2 positivity might be introduced as part of the routine investigation in patients with DLBCL, but further studies are necessary to confirm the clinical relevance of Ki-67 and TP53 expression.
      datePublished:2004-04-14T00:00:00Z
      dateModified:2004-04-14T00:00:00Z
      pageStart:414
      pageEnd:419
      sameAs:https://doi.org/10.1007/s00277-004-0855-x
      keywords:
         BCL2
         Diffuse large B-cell lymphoma
         P-glycoprotein
         Proliferation
         TP53
         Hematology
         Oncology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb1.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb2.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb3.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs00277-004-0855-x/MediaObjects/s00277-004-0855-xflb4.gif
      isPartOf:
         name:Annals of Hematology
         issn:
            1432-0584
            0939-5555
         volumeNumber:83
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:M. Jerkeman
            affiliation:
                  name:Lund University Hospital
                  address:
                     name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:H. Anderson
            affiliation:
                  name:Lund University Hospital
                  address:
                     name:Department of Cancer Epidemiology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Dictor
            affiliation:
                  name:Lund University Hospital
                  address:
                     name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:S. Kvaløy
            affiliation:
                  name:Norwegian Radium Hospital, Montebello
                  address:
                     name:Department of Oncology, Norwegian Radium Hospital, Montebello, Oslo, Norway
                     type:PostalAddress
                  type:Organization
            type:Person
            name:M. Åkerman
            affiliation:
                  name:Lund University Hospital
                  address:
                     name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
            name:E. Cavallin-Ståhl
            affiliation:
                  name:Lund University Hospital
                  address:
                     name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Hematology
      issn:
         1432-0584
         0939-5555
      volumeNumber:83
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Lund University Hospital
      address:
         name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
         type:PostalAddress
      name:Lund University Hospital
      address:
         name:Department of Cancer Epidemiology, Jubileum Institute, Lund University Hospital, Lund, Sweden
         type:PostalAddress
      name:Lund University Hospital
      address:
         name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
         type:PostalAddress
      name:Norwegian Radium Hospital, Montebello
      address:
         name:Department of Oncology, Norwegian Radium Hospital, Montebello, Oslo, Norway
         type:PostalAddress
      name:Lund University Hospital
      address:
         name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
         type:PostalAddress
      name:Lund University Hospital
      address:
         name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:M. Jerkeman
      affiliation:
            name:Lund University Hospital
            address:
               name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:H. Anderson
      affiliation:
            name:Lund University Hospital
            address:
               name:Department of Cancer Epidemiology, Jubileum Institute, Lund University Hospital, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:M. Dictor
      affiliation:
            name:Lund University Hospital
            address:
               name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:S. Kvaløy
      affiliation:
            name:Norwegian Radium Hospital, Montebello
            address:
               name:Department of Oncology, Norwegian Radium Hospital, Montebello, Oslo, Norway
               type:PostalAddress
            type:Organization
      name:M. Åkerman
      affiliation:
            name:Lund University Hospital
            address:
               name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
               type:PostalAddress
            type:Organization
      name:E. Cavallin-Ståhl
      affiliation:
            name:Lund University Hospital
            address:
               name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
      name:Department of Cancer Epidemiology, Jubileum Institute, Lund University Hospital, Lund, Sweden
      name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
      name:Department of Oncology, Norwegian Radium Hospital, Montebello, Oslo, Norway
      name:Department of Pathology, Jubileum Institute, Lund University Hospital, Lund, Sweden
      name:Department of Oncology, Jubileum Institute, Lund University Hospital, Lund, Sweden
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(83)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Foundation
Prism.js

CDN Services {📦}

Crossref

4.13s.

LINK . SPRINGER . COM {}